Vascular Biogenics - Stock Price History | VBLT

Historical daily share price chart and data for Vascular Biogenics since 2021 adjusted for splits. The latest closing stock price for Vascular Biogenics as of October 26, 2021 is 2.36.
  • The all-time high Vascular Biogenics stock closing price was 16.23 on January 27, 2015.
  • The Vascular Biogenics 52-week high stock price is 3.17, which is 34.3% above the current share price.
  • The Vascular Biogenics 52-week low stock price is 1.01, which is 57.2% below the current share price.
  • The average Vascular Biogenics stock price for the last 52 weeks is 2.07.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Vascular Biogenics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 1.3149 1.2500 2.0000 0.9600 1.8900 57.50%
2019 1.2975 0.9933 1.7500 0.9390 1.2000 23.71%
2018 2.7547 7.2000 8.5000 0.6000 0.9700 -86.34%
2017 5.6047 5.0500 9.0000 4.0500 7.1000 46.39%
2016 4.0998 5.0900 6.8500 2.8000 4.8500 -7.79%
2015 6.4981 6.7500 16.2300 3.1900 5.2600 -11.00%
2014 6.1826 5.8500 6.9500 5.5000 5.9100 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.147B $0.001B
Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86